Gastrointestinal side effects associated with novel therapies in patients with multiple myeloma: Consensus statement of the IMF nurse leadership board

Clinical Journal of Oncology Nursing

Volumn 12, Issue SUPPL. 3, 2008, Pages 37-51

  Smith, Lisa C ^a   Bertolotti, Page ^b   Curran, Kathleen ^c   Jenkins, Bonnie ^d  

^a Cancer Centers of the Carolinas   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; DRUG EFFECT; GASTROINTESTINAL TRACT; HUMAN; LEADERSHIP; MULTIPLE MYELOMA; NURSING ORGANIZATION; PATHOPHYSIOLOGY; RISK FACTOR;

ANTINEOPLASTIC AGENTS; GASTROINTESTINAL TRACT; HUMANS; LEADERSHIP; MULTIPLE MYELOMA; RISK FACTORS; SOCIETIES, NURSING;

EID: 49649116640     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/08.CJON.S1.37-51     Document Type: Article

References (39)

1. American Gastroenterological Association. (2000). AGA guideline: Constipation. Gastroenterology, 119, 1761-1778.
2. American Society of Clinical Oncology. (2005a). Constipation. Retrieved October 18, 2007, from http://www.asco.org/portal/site/patient/menuitem.169f5d85214941ccfd748f68ee37a01d/?vgnextoid=d9f041eca8daa010VgnVCM100000ed730ad1RCRD
3. American Society of Clinical Oncology. (2005b). Diarrhea. Retrieved October 18, 2007, from http://www.asco.org/portal/site/patient/menuitem.169f5d85214941ccfd748f68ee37a01d/?vgnextoid=def041eca8daa010VgnVCM100000ed730ad1RCRD
4. American Society of Clinical Oncology.(2005c). Nausea and vomiting. Retrieved October 18, 2007, from http://www.asco.org/portal/site/patient/menuitem.169f5d85214941ccfd748f68ee37a01d/?vgnextoid=2f0141eca8daa010VgnVCM100000ed730ad1RCRD&cpsextcurrchannel=1
5. Basch, E.M., & Ulbricht, C.E. (2004). Complementary, alternative, and integrative therapies in cancer care. In V.T. DeVita, S. Hellman, & S.A. Rosenberg (Eds.), Cancer: Principles and practice of oncology (7th ed.). Philadelphia: Lippincott Williams and Wilkins.
6. Benson, A.B., Ajani, J.A., Catalano, R.B., Engelking, C., Kornblau, S.M., Martenson, J.A., et al. (2004). Recommended guidelines for the treatment of cancer treatment-induced diarrhea. Journal of Clinical Oncology, 22(14), 2918-2926.
7. Berger, A.M., & Clark-Snow, R.A. (2005). Nausea and vomiting. In V.T. DeVita, S. Hellman, & S.A. Rosenberg (Eds.), Cancer: Principles and practice of oncology (7th ed.). Philadelphia: Lippincott Williams and Wilkins.
8. Berger, A.M., & Clark-Snow, R.A. (2007). Chemotherapy-related nausea and vomiting. In A.M. Berger, J.L. Shuster, & J.H. Von Roenn (Eds.), Principles and practice of palliative care and supportive oncology (3rd ed.). Philadelphia: Lippincott Williams and Wilkins.
9. Bertolotti, P., Bilotti, E., Colson, K., Curran, K., Doss, D., Faiman, B., et al. (2007). Nursing guidelines for enhanced patient care. Haematologica, 92(Suppl. 2), 211.
10. Bertolotti, P., Bilotti, E., Colson, K., Curran, K., Doss, D., Faiman, B., et al. (2008). Management of side effects of novel therapies for multiple myeloma: Consensus statements developed by the International Myeloma Foundation's Nurse Leadership Board. Clinical Journal of Oncology Nursing, 12(3, Suppl.), 9-12.
11. Bisanz, A., Woolery, M., Lyons, H.F, Gaido, L., Yenulevich, M.C., & Fulton, S. (2007). Putting Evidence Into Practice®: Constipation. Retrieved October 29, 2007, from http://www.ons.org/outcomes/volume2/constipation.shtml
12. Bush, N. (2004). Chemotherapy-induced diarrhea. Oncology Nursing Forum, 31(5), 889-892.
13. Celgene Corporation. (2007a). Revlimid® (lenalidomide) [Package insert]. Summit, NJ: Author.
14. Celgene Corporation. (2007b). Thalomid® (thalidomide) [Package insert]. Summit, NJ: Author.
15. Dalal, S., Palat, G., & Bruera, E. (2007). Chronic nausea and vomiting. In A.M. Berger, J.L. Shuster, & J.H. Von Roenn (Eds.), Principles and practice of palliative care and supportive oncology (3rd ed.). Philadelphia: Lippincott Williams and Wilkins.
16. Engelking, C. (2004). Diarrhea. In C.H. Yarbro, M.H. Frogge, & M. Goodman (Eds.), Cancer symptom management (3rd ed., pp. 528-556). Sudbury, MA: Jones and Bartlett.
17. Ernst, E., & Pittler, M.H. (2000). Efficacy of ginger for nausea and vomiting: A systematic review of randomized clinical trials. British Journal of Anaesthesia, 84(3), 367-371.
18. Ghobrial, J., Ghobrial, I.M., Mitsiades, C., Leleu, X., Hatjiharissi, E., Moreau, A.S., et al. (2007). Novel therapeutic avenues in myeloma: Changing the treatment paradigm. Oncology, 21(7), 785-792.
19. Glare, P., Pereira, G., Kristjanson, L.J., Stockler, M., & Tattersall, M. (2004). Systematic review of the efficacy of antiemetics in the treatment of nausea in patients with far-advanced cancer. Supportive Care in Cancer, 12(6), 432-440.
20. Grunberg, S.M. (2007). Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: Dosing, efficacy and tolerability analysis. Annals of Oncology, 18(2), 233-240.
21. Hofman, M., Morrow, G.R., Roscoe, J.A., Hickok, J.T., Mustian, K.M., Moore, D.F., et al. (2004). Cancer patient's expectations of experiencing treatment-related side effects: A University of Rochester Cancer Center-Community Clinical Oncology Program study of 938 patients from community practices. Cancer, 101(4), 851-857.
22. Jordan, K., Sippel, C., & Schmoll, H.J. (2007). Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: Past, present, and future recommendations. Oncologist, 12(9), 1143-1150.
23. Kris, M.G., Hesketh, P.J., Somerfield, M.R., Feyer, P., Clark-Snow, R., Koeller, J.M., et al. (2006). American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006. Journal of Clinical Oncology, 24(18), 2932-2947.
24. Manochakian, R., Miller, K.C., & Chanan-Khan, A.A. (2007). Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma. Oncologist, 12(8), 978-990.
25. rd ed.). Philadelphia: Lippincott Williams and Wilkins.
26. Millennium Pharmaceuticals, Inc. (2007). Velcade® (bortezomib) [Package insert]. Cambridge, MA: Author.
27. Molassiotis, A., Yung, H.P., Yam, B.M., Chan, F.Y., & Mok, T.S. (2002). The effectiveness of progressive muscle relaxation training in managing chemotherapy-induced nausea and vomiting in Chinese breast cancer patients: A randomized controlled trial. Supportive Care in Cancer, 10(3), 237-246.
28. National Cancer Institute. (2006). Common Terminology Criteria for Adverse Events v.3.0. Retrieved December 28, 2007, from http://ctep.cancer.gov/forms/CTCAEv3.pdf
29. National Cancer Institute. (2007a). Gastrointestinal complications (PDQ®). Retrieved October 29, 2007, from http://www.cancer.gov/cancertopics/pdq/supportivecare/gastrointestinalcomplications/HealthProfessional
30. National Cancer Institute. (2007b). Nausea and vomiting (PDQ®) Retrieved October 29, 2007, from http://www.cancer.gov/cancertopics/pdq/supportivecare/nausea/healthprofessional/allpages
31. National Comprehensive Cancer Network. (2007). NCCN Clinical Practice Guidelines in Oncology™: Antiemesis [v.3.2008]. Retrieved September 10, 2007, from http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf
32. National Comprehensive Cancer Network & American Cancer Society. (2007). Nausea and vomiting: Treatment guidelines for patients with cancer. Retrieved September 10, 2007, from http://www.nccn.org/patients/patient_gls/_english/pdf/NCCN%20Nausea%20Guidelines.pdf
33. Rajkumar, S.V., Hayman, S.R., Lacy, M.Q., Dispenzieri, A., Geyer, S.M., Kabat, B., et al. (2005). Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood, 106(13), 4050-4053.
34. Redd, W.H., Montgomery, G.H., & DuHamel, K.N. (2001). Behavioral intervention for cancer treatment. Journal of the National Cancer Institute, 93(11), 810-823.
35. Richardson, P.G., & Anderson, K. (2006). Thalidomide and dexamethasone: A new standard of care for initial therapy in multiple myeloma. Journal of Clinical Oncology, 24(3), 334-336.
36. Richardson, P.G., Hideshima, T., Mitsiades, C., & Anderson, K.C. (2007). The emerging role of novel therapies for the treatment of relapsed myeloma. Journal of the National Comprehensive Cancer Network, 5(2), 149-162.
37. San Miguel, J., Blade, J., Boccadoro, M., Cavenagh, J., Glassmacher, A., Jagannath, S., et al. (2006). A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist, 11(1), 51-61.
38. Shen, J., Wenger, N., Glaspy, J., Hays, R.D., Albert, P.S., Choi, C., et al. (2000). Electro acupuncture for control of myeloablative chemotherapy-induced emesis: A randomized controlled trial. JAMA, 284(21), 2755-2761.
39. Tipton, J., McDaniel, R., Barbour, L., Johnston, M.P., LeRoy, P., Kayne, M., et al. (2006). Putting Evidence into Practice®: Chemotherapy induced nausea and vomiting. Retrieved October 29, 2007, from http://www.ons.org/outcomes/volume1/nausea.shtml